Trials / Completed
CompletedNCT00267488
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | topotecan |
Timeline
- Start date
- 2005-10-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2005-12-21
- Last updated
- 2012-07-11
- Results posted
- 2010-01-28
Locations
24 sites across 3 countries: United States, Canada, Hungary
Source: ClinicalTrials.gov record NCT00267488. Inclusion in this directory is not an endorsement.